Bevacizumab Induced Changes in Circulating Plasma Analytes and Immune Cells
When comparing patients who received bevacizumab relative to those who did not receive bevacizumab (Treatment effect of combining bevacizumab with avelumab. There were multiple significantly differentially expressed cytokines between samples from patients who were treated with avelumab and bevacizumab compared with samples from the same patients who were not treated with bevacizumab (The median PD-L1 expression in plasma samples increased by 1.8-fold after avelumab treatment and maintained the same fold difference when avelumab was combined with bevacizumab compared with baseline (CyTOF was used to analyze specific circulating immune cell populations. There was no difference in the circulating immune cell subsets in the samples collected at baseline or after avelumab treatment. However, there was a significant decline in γδT cells (